ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

FRONTPRO 11 mg chewable tablets for dogs 2–4 kg
FRONTPRO 28 mg chewable tablets for dogs >4–10 kg
FRONTPRO 68 mg chewable tablets for dogs >10–25 kg
FRONTPRO 136 mg chewable tablets for dogs >25–50 kg

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each chewable tablet contains:

**Active substance:**

<table>
<thead>
<tr>
<th>FRONTPRO</th>
<th>Afoxolaner (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>chewable tablets for dogs 2–4 kg</td>
<td>11.3</td>
</tr>
<tr>
<td>chewable tablets for dogs &gt;4–10 kg</td>
<td>28.3</td>
</tr>
<tr>
<td>chewable tablets for dogs &gt;10–25 kg</td>
<td>68</td>
</tr>
<tr>
<td>chewable tablets for dogs &gt;25–50 kg</td>
<td>136</td>
</tr>
</tbody>
</table>

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Chewable tablets.

Mottled red to reddish brown, circular shaped (tablets for dogs 2–4 kg) or rectangular shaped (tablets for dogs >4–10 kg, tablets for dogs >10–25 kg and tablets for dogs >25–50 kg).

4. **CLINICAL PARTICULARS**

4.1 **Target species**

Dogs.

4.2 **Indications for use, specifying the target species**

Treatment of flea infestation in dogs (*Ctenocephalides felis* and *C. canis*) for at least 5 weeks. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

Treatment of tick infestation in dogs (*Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus*). One treatment kills ticks for up to one month.

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

Treatment of demodicosis (caused by *Demodex canis*).

Treatment of sarcoptic mange (caused by *Sarcoptes scabiei var. canis*).

4.3 **Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
4.4 Special warnings for each target species

Parasites need to start feeding on the host to become exposed to afoxolaner; therefore the risk of the transmission of parasite borne diseases cannot be excluded.

4.5 Special precautions for use

Special precautions for use in animals

In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 2 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

To prevent children from getting access to the veterinary medicinal product, remove only one chewable tablet at a time from the blister. Return the blister with the remaining chewable tablets into the carton.

Wash hands after handling the product.

4.6 Adverse reactions (frequency and seriousness)

Mild gastrointestinal effects (vomiting, diarrhoea), pruritus, lethargy, anorexia, and neurological signs (convulsions, ataxia and muscle tremors) have been reported very rarely. Most reported adverse reactions were self-limiting and of short duration.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

Laboratory studies in rats and rabbits have not produced any evidence of teratogenic effects, or any adverse effect on the reproductive capacity of males and females.

The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in breeding dogs. Use only according to the benefit-risk assessment by the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

None known.

4.9 Amounts to be administered and administration route

For oral use.

Dosage:
The product should be administered at a dose of 2.7–7 mg/kg bodyweight in accordance with the following table:
Bodyweight of dog (kg) & Strength and number of chewable tablets to be administered

<table>
<thead>
<tr>
<th></th>
<th>FRONTPRO 11 mg</th>
<th>FRONTPRO 28 mg</th>
<th>FRONTPRO 68 mg</th>
<th>FRONTPRO 136 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>2–4</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;4–10</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;10–25</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;25–50</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

For dogs above 50 kg bodyweight, use an appropriate combination of chewable tablets of different/same strengths. The tablets should not be divided.

Method of administration:
The tablets are chewable and palatable to most dogs. If the dog does not accept the tablets directly they may be administered with food.

Treatment schedule:

*Treatment of flea and tick infestations:*
Monthly intervals throughout the flea and/or tick seasons, based on local epidemiological situations.

*Treatment of demodicosis (caused by *Demodex canis)*:
Monthly administration of the product until two negative skin scrapings are obtained one month apart. Severe cases may require prolonged monthly treatments. As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.

*Treatment of sarcoptic mange (caused by *Sarcoptes scabiei var. canis)*:
Monthly administration of the product for two consecutive months. Further monthly administration of the product may be required based on clinical assessment and skin scrapings.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No adverse reactions were observed in healthy Beagle puppies over 8 weeks of age when treated with 5 times the maximum dose repeated 6 times at intervals of two to four weeks.

4.11 Withdrawal period(s)

Not applicable.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Ectoparasiticides for systemic use.
ATC vet code: QP53BE01.

5.1 Pharmacodynamic properties

Afoxolaner is an insecticide and acaricide belonging to the isoxazoline family. Afoxolaner acts at ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes. This results in uncontrolled activity of the central nervous system and death of insects or acarines. The selective toxicity of afoxolaner between insect/acarines and mammals may be inferred by the differential sensitivity of the insect/acarines’ GABA receptors versus mammalian receptors.

Afoxolaner is active against adult fleas as well as several tick species such as *Dermacentor reticulatus* and *D. variabilis, Ixodes ricinus* and *I. scapularis, Rhipicephalus sanguineus, Amblyomma americanum* and *Haemaphysalis longicornis*.

FRONTPRO kills fleas within 8 hours and ticks within 48h.
The product kills fleas before egg production and therefore prevents household contamination.

5.2 Pharmacokinetic particulars

After oral administration in dogs, afoxolaner was shown to have high systemic absorption following administration. The absolute bioavailability was 74%. The mean maximum concentration ($C_{\text{max}}$) was $1,655 \pm 332 \text{ ng/ml}$ in plasma at 2–4 hours ($T_{\text{max}}$) after a 2.5 mg/kg afoxolaner dose. Afoxolaner distributes into tissues with a volume of distribution of $2.6 \pm 0.6 \text{ l/kg}$ and a systemic clearance value of $5.0 \pm 1.2 \text{ ml/hr/kg}$. The terminal plasma half-life is approximately 2 weeks in most dogs; however, half-life of afoxolaner can differ between dogs (e.g. in one study, $t_{1/2}$ in Collies at 25 mg/kg bodyweight was up to 47.7 days) with no effect on safety. In-vitro experiments demonstrated that P-glycoprotein efflux does not occur, confirming that afoxolaner is not a substrate for the P-glycoprotein transporters. Afoxolaner in the dog is metabolised to more hydrophilic compounds and then eliminated. The metabolites and parent compound are eliminated from the body via urinary and biliary excretion with the majority eliminated in the bile. No evidence of enterohepatic recycling has been observed.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Maize starch
Soy protein fines
Braised beef flavouring
Povidone (E1201)
Macrogol 400
Macrogol 4000
Macrogol 15 hydroxystearate
Glycerol (E422)
Medium-chain triglycerides

6.2 Major incompatibilities

Not applicable.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

6.4 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

6.5 Nature and composition of immediate packaging

The veterinary medicinal product is individually packaged in thermoformed laminated PVC blisters with paper-backed aluminium (Aclar/PVC/Alu).

One carton contains one blister of 1, 3 or 6 chewable tablets or 15 blisters of 1 chewable tablet.

Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
GERMANY

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/19/240/001–016

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 20/05/2019

10. DATE OF REVISION OF THE TEXT

{DD/MM/YYYY}

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu).

PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.
ANNEX II

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
C. STATEMENT OF THE MRLs
D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORIZATION
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Boehringer Ingelheim Animal Health France SCS
4 Chemin du Calquet
31000 Toulouse
FRANCE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

C. STATEMENT OF THE MRLs

Not applicable.

D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORIZATION

Specific pharmacovigilance requirements:

The periodic safety update report (PSUR) submissions shall be synchronised and submitted at the same frequency as for the reference product.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Carton

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

FRONTPRO 11 mg chewable tablets for dogs 2–4 kg
FRONTPRO 28 mg chewable tablets for dogs >4–10 kg
FRONTPRO 68 mg chewable tablets for dogs >10–25 kg
FRONTPRO 136 mg chewable tablets for dogs >25–50 kg

Afoxolaner

2. STATEMENT OF ACTIVE SUBSTANCES

Afoxolaner 11.3 mg
Afoxolaner 28.3 mg
Afoxolaner 68 mg
Afoxolaner 136 mg

3. PHARMACEUTICAL FORM

Chewable tablets

4. PACKAGE SIZE

1 tablet
3 tablets
6 tablets
15 tablets

5. TARGET SPECIES

Dogs 2–4 kg
Dogs >4–10 kg
Dogs >10–25 kg
Dogs >25–50 kg

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

8. WITHDRAWAL PERIOD(S)
9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}

11. SPECIAL STORAGE CONDITIONS

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
GERMANY

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/19/240/001
EU/2/19/240/002
EU/2/19/240/003
EU/2/19/240/004
EU/2/19/240/005
EU/2/19/240/006
EU/2/19/240/007
EU/2/19/240/008
EU/2/19/240/009
EU/2/19/240/010
EU/2/19/240/011
EU/2/19/240/012
EU/2/19/240/013
EU/2/19/240/014
17. MANUFACTURER’S BATCH NUMBER

Lot
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

**Blister**

1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

   FRONTPRO 11 mg dogs 2–4 kg  
   FRONTPRO 28 mg dogs >4–10 kg  
   FRONTPRO 68 mg dogs >10–25 kg  
   FRONTPRO 136 mg dogs >25–50 kg  

   afoxolaner

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**

   ![Boehringer Ingelheim](image)

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **THE WORDS “FOR ANIMAL TREATMENT ONLY”**

   For animal treatment only.
B. PACKAGE LEAFLET
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
GERMANY

Manufacturer responsible for batch release:
Boehringer Ingelheim Animal Health France SCS
4 Chemin du Calquet
31000 Toulouse
FRANCE

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

FRONTPRO 11 mg chewable tablets for dogs (2–4 kg)
FRONTPRO 28 mg chewable tablets for dogs (>4–10 kg)
FRONTPRO 68 mg chewable tablets for dogs (>10–25 kg)
FRONTPRO 136 mg chewable tablets for dogs (>25–50 kg)
afoxolaner

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each chewable tablet contains:

<table>
<thead>
<tr>
<th>FRONTPRO</th>
<th>Afoxolaner (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>chewable tablets for dogs 2–4 kg</td>
<td>11.3</td>
</tr>
<tr>
<td>chewable tablets for dogs &gt;4–10 kg</td>
<td>28.3</td>
</tr>
<tr>
<td>chewable tablets for dogs &gt;10–25 kg</td>
<td>68</td>
</tr>
<tr>
<td>chewable tablets for dogs &gt;25–50 kg</td>
<td>136</td>
</tr>
</tbody>
</table>

Mottled red to reddish brown, circular shaped (tablets for dogs 2–4 kg), or rectangular shaped (tablets for dogs >4–10 kg, tablets for dogs >10–25 kg and tablets for dogs >25–50 kg).

4. INDICATION(S)

Treatment of flea infestation in dogs (*Ctenocephalides felis* and *C. canis*) for at least 5 weeks. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

Treatment of tick infestation in dogs (*Dermacentor reticulatus*, *Ixodes ricinus*, *Rhipicephalus sanguineus*). One treatment kills ticks for up to one month.

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

Treatment of demodicosis (caused by *Demodex canis*).
Treatment of sarcoptic mange (caused by *Sarcoptes scabiei var. canis*).

5. **CONTRAINDICATIONS**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. **ADVERSE REACTIONS**

Mild gastrointestinal effects (vomiting, diarrhoea), pruritus, lethargy, anorexia, and neurological signs (convulsions, ataxia and muscle tremors) have been reported very rarely. Most reported adverse reactions were self-limiting and of short duration.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s)).
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. **TARGET SPECIES**

Dogs

8. **DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

For oral use

**Dosage:**
The product should be administered in accordance with the following table to ensure a dose of 2.7-7 mg/kg bodyweight.

<table>
<thead>
<tr>
<th>Bodyweight of dog (kg)</th>
<th>Strength and number of chewable tablets to be administered</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FRONTPRO 11 mg</td>
</tr>
<tr>
<td>2–4</td>
<td>1</td>
</tr>
<tr>
<td>&gt;4–10</td>
<td>1</td>
</tr>
<tr>
<td>&gt;10–25</td>
<td>1</td>
</tr>
<tr>
<td>&gt;25–50</td>
<td>1</td>
</tr>
</tbody>
</table>

For dogs above 50 kg bodyweight, use an appropriate combination of chewable tablets of different/same strengths.
The tablets should not be divided.

**Treatment schedule:**

*Treatment of flea and tick infestations:*
Monthly intervals throughout the flea and/or tick seasons, based on local epidemiological situations.
Treatment of demodicosis (caused by *Demodex canis*):
Monthly administration of the product until two negative skin scrapings are obtained one month apart.
Severe cases may require prolonged monthly treatments. As demodicosis is a multi-factorial disease,
where possible, it is advisable to also treat any underlying disease appropriately.

Treatment of sarcoptic mange (caused by *Sarcoptes scabiei var. canis*):
Monthly administration of the product for two consecutive months. Further monthly administration of
the product may be required based on clinical assessment and skin scrapings.

9. ADVICE ON CORRECT ADMINISTRATION

FRONTPRO tablets are chewable and palatable to most dogs. If the dog does not accept the tablets
directly they may be administered with food.

10. WITHDRAWAL PERIOD(S)

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton after
EXP. The expiry date refers to the last day of that month.
This veterinary medicinal product does not require any special storage conditions.

12. SPECIAL WARNING(S)

Special warnings for each target species:
Parasites need to start feeding on the host to become exposed to afoxolaner; therefore the risk of the
transmission of parasite borne diseases cannot be excluded.

Special precautions for use in animals:
In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 2 kg
bodyweight should be based on a benefit-risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
To prevent children from getting access to the veterinary medicinal product, remove only one chewable
tablet at a time from the blister. Return the blister with the remaining chewable tablets into the carton.
Wash hands after handling the product.

Pregnancy and lactation:
Laboratory studies in rats and rabbits have not produced any evidence of teratogenic effects, or any
adverse effect on the reproductive capacity of males and females. The safety of the veterinary medicinal
product has not been established during pregnancy and lactation or in breeding dogs. Use only according
to the benefit-risk assessment by the responsible veterinarian.

Overdose (symptoms, emergency procedures, antidotes):
No adverse reactions were observed in healthy Beagle puppies over 8 weeks of age when treated with
5 times the maximum dose repeated 6 times at intervals of 2-4 weeks.
13. **SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

14. **DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu).

15. **OTHER INFORMATION**

Afoxolaner is an insecticide and acaricide belonging to the isoxazoline family.

FRONTPRO is active against adult fleas as well as several tick species such as *Dermacentor reticulatus* and *D. variabilis*, *Ixodes ricinus* and *I. scapularis*, *Rhipicephalus sanguineus*, *Amblyomma americanum*, and *Haemaphysalis longicornis*.

FRONTPRO kills fleas within 8 hours and ticks within 48h.

The product kills fleas before egg production and therefore prevents household contamination.

For each strength, the chewable tablets are available in the following pack sizes:
Carton with 1 blister of 1, 3 or 6 chewable tablets or 15 blisters of 1 chewable tablet.

Not all pack sizes may be marketed.